Regenexx Corporate Program

Receive Patient Referrals with the Regenexx Corporate Program

Trusted by over 2,000 self-funded employers, the Regenexx Corporate Program delivers musculoskeletal care referrals directly to licensed physicians.

How It Works: Physician Referral Flow

1. Employer or group adds Regenexx as a covered MSK benefit.

2. Employee or member accesses their Regenexx Benefit independently or through employer supported targeted outreach and member education.

3. Employee requests referral and is pre-screened by the Regenexx Patient Liaison Team to confirm their benefit details.

4. Referral is sent to physician for evaluation and treatment

Employer Outcomes

Real Employers. Real Results.

“Our 6-month study of Regenexx benefit cases that were all surgically bound have been remarkable. All 8 cases referred to the Regenexx benefit have avoided surgery, recovered extremely well, and returned to work within 7 days or less.”

Andrew L. Davala, Viking Yacht Company

“Dr. Lendermon, looked at my x-rays and said she really was pretty certain that she could really help me. She said a lot of people are told that the next step when you’re bone on bone is a knee replacement and they said, “No, we think we can do better than that. We think we can give you a lot of relief.” She said, “We can’t give you 18 year old knees, but we ought to be able to give you a lot of relief for the next 10 to 15 years.”

Mark V., Clearent by Xplor

“Prior to Regenexx, it was either ‘be in pain’ or ‘get surgery’ and that surgery could affect my lifestyle in that it wasn’t 100% guaranteed and because I’m an active person I was worried that I would be limited physically after fusion surgery. So, while that still might be in my future, Regenexx certainly gave me back my ability to live a lifestyle the way I want to live it.”

Brian M., McGohan Brabender

A Program and Benefit Built on Clinical Rigor

The Regenexx benefit can be confidently added to a self-funded health plan because the Regenexx approach to MSK care, with its proprietary methods and injectates, is uniquely positioned to meet the five key criteria insurers use to evaluate investigational treatments, including:

Safety: Largest published safety dataset in orthobiologics
Efficacy: Peer-reviewed RCTs on PRP (platelet rich plasma) and BMC (bone marrow concentrate which contains stem cells)
Regulatory Pathway: Regenexx is compliant with FDA’s 21 CFR 1271.15(b)
Comparable to Standard of Care: Often equal or superior to orthopedic surgery
Prevalence: In use outside clinical trials since 2005